JP2007511216A - 変異ウイルス - Google Patents

変異ウイルス Download PDF

Info

Publication number
JP2007511216A
JP2007511216A JP2006538967A JP2006538967A JP2007511216A JP 2007511216 A JP2007511216 A JP 2007511216A JP 2006538967 A JP2006538967 A JP 2006538967A JP 2006538967 A JP2006538967 A JP 2006538967A JP 2007511216 A JP2007511216 A JP 2007511216A
Authority
JP
Japan
Prior art keywords
herpes simplex
simplex virus
nucleic acid
sequence
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511216A5 (enExample
Inventor
ブラウン，スザンヌ，モイラ
ダン，ポール
シング，ブヴァネシュ
ガンリー，イアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0326798.6A external-priority patent/GB0326798D0/en
Application filed by Individual filed Critical Individual
Publication of JP2007511216A publication Critical patent/JP2007511216A/ja
Publication of JP2007511216A5 publication Critical patent/JP2007511216A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006538967A 2003-11-17 2004-11-17 変異ウイルス Pending JP2007511216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
US54130804P 2004-02-03 2004-02-03
PCT/GB2004/004908 WO2005049846A2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer

Publications (2)

Publication Number Publication Date
JP2007511216A true JP2007511216A (ja) 2007-05-10
JP2007511216A5 JP2007511216A5 (enExample) 2008-01-10

Family

ID=34621663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538967A Pending JP2007511216A (ja) 2003-11-17 2004-11-17 変異ウイルス

Country Status (4)

Country Link
US (2) US20070003520A1 (enExample)
EP (1) EP1694852B1 (enExample)
JP (1) JP2007511216A (enExample)
WO (1) WO2005049846A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522854A (ja) * 2018-05-01 2021-09-02 アルベルト・アインシュタイン・カレッジ・オブ・メディシンＡｌｂｅｒｔ Ｅｉｎｓｔｅｉｎ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ ＨＳＶ−２−ＤＥＬＴＡ−ｇＤ ワクチンおよびそれらの生産および使用のための方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
JP5442452B2 (ja) * 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
WO2012106529A1 (en) * 2011-02-02 2012-08-09 The Trustees Of Princeton University Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2662117A1 (en) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus for the treatment of liver cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
GB201520345D0 (en) * 2015-11-18 2015-12-30 Virttu Biolog Ltd Herpes simplex viruses
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018115458A1 (en) 2016-12-23 2018-06-28 Virttu Biologics Limited Treatment of cancer
CA3052473A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
IL319966A (en) 2017-03-16 2025-05-01 Alpine Immune Sciences Inc CD80 Variant Immune Modulator Proteins and Uses Thereof
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
TW202500579A (zh) 2017-10-18 2025-01-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
ES2966045T3 (es) 2018-06-04 2024-04-18 Calidi Biotherapeutics Inc Vehículos basados en células para la potenciación de la terapia viral
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
MX2021010273A (es) 2019-02-27 2021-09-23 Actym Therapeutics Inc Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
WO2025129492A1 (zh) * 2023-12-20 2025-06-26 中国科学院深圳先进技术研究院 一种减毒单纯疱疹病毒在制备神经环路逆向示踪工具病毒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038805A2 (en) * 2000-11-09 2002-05-16 Cenix Bioscience Gmbh Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
JP2003520789A (ja) * 2000-01-21 2003-07-08 バイオヴェックス リミテッド ウイルス株
WO2003068809A2 (en) * 2002-02-12 2003-08-21 Crusade Laboratories Limited An herpes simplex virus complex

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
AU623913B2 (en) 1988-06-24 1992-05-28 British Technology Group Limited Fowlpox virus non-essential regions
EP1380651A2 (en) 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
IL118942A (en) 1995-07-27 2002-09-12 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines
JPH11513565A (ja) 1995-10-19 1999-11-24 セント ジュード チルドレンズ リサーチ ホスピタル ヘルペスウィルスベクター及びその利用
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
WO2000034497A2 (en) * 1998-12-09 2000-06-15 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
AU781219B2 (en) 1999-08-31 2005-05-12 General Hospital Corporation, The Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
US20030073099A1 (en) * 2000-04-18 2003-04-17 Tang Y. Tom Novel nucleic acids and polypeptides
AU2002230895A1 (en) * 2000-12-21 2002-07-01 Myriad Genetics, Inc. Protein-protein interactions
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー，アン，ジョセフィーヌ 遺伝子発現のサイレンシング
US7348418B2 (en) * 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
GB2450843B (en) 2006-05-11 2011-02-09 Crusade Lab Ltd Mutant HSV, materials and methods for generation of mutant HSV
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520789A (ja) * 2000-01-21 2003-07-08 バイオヴェックス リミテッド ウイルス株
WO2002038805A2 (en) * 2000-11-09 2002-05-16 Cenix Bioscience Gmbh Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
WO2003068809A2 (en) * 2002-02-12 2003-08-21 Crusade Laboratories Limited An herpes simplex virus complex

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522854A (ja) * 2018-05-01 2021-09-02 アルベルト・アインシュタイン・カレッジ・オブ・メディシンＡｌｂｅｒｔ Ｅｉｎｓｔｅｉｎ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ ＨＳＶ−２−ＤＥＬＴＡ−ｇＤ ワクチンおよびそれらの生産および使用のための方法
JP7671982B2 (ja) 2018-05-01 2025-05-07 アルベルト・アインシュタイン・カレッジ・オブ・メディシン ＨＳＶ－２－ＤＥＬＴＡ－ｇＤ ワクチンおよびそれらの生産および使用のための方法

Also Published As

Publication number Publication date
WO2005049846A9 (en) 2006-10-19
WO2005049846A3 (en) 2005-10-06
EP1694852B1 (en) 2010-10-13
EP1694852A2 (en) 2006-08-30
US20090274728A1 (en) 2009-11-05
US8530437B2 (en) 2013-09-10
WO2005049846A2 (en) 2005-06-02
US20070003520A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
US8530437B2 (en) Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene
EP2281897A2 (en) Oncolytic mutant Herpes Simplex virus
KR101177659B1 (ko) 바이러스 벡터
AU712793B2 (en) Viral vectors
JPH11506931A (ja) 腫瘍または細胞特異的な単純ヘルペスウイルスの複製
Grandi et al. Design and application of oncolytic HSV vectors for glioblastoma therapy
EP2016182B1 (en) Mutant hsv, materials and methods for generation of mutant hsv
JP2001508294A (ja) 真核細胞遺伝子発現カセットおよびその使用
WO2017085175A1 (en) Herpes simplex viruses
CN111041001B (zh) 治疗kras突变型肿瘤的安全型柯萨奇病毒及其药物组合物
WO2020112471A1 (en) New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
EP2239325A1 (en) Virus growing in hypoxic cell or virus vector expressing gene therein
US7371570B2 (en) Cell-specific adenovirus vector comprising EBV-specific promoter
CN101516908B (zh) 用于在哺乳动物癌细胞中表达目的多核苷酸的核酸
EP1469077B1 (en) Cell-specific expression/replication vector
CN100489091C (zh) 可分泌血管抑素和内皮抑素蛋白的重组单疱疹病毒及其在治疗肺癌中的应用
CN113943715B (zh) 一种重组溶瘤基因腺病毒及其构建方法与应用
WO1998030708A1 (en) Sv40 viral vectors for targeted integration into cells
WO2004070041A1 (en) Vectors for expression of toxins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071114

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110920